IMMU - Immunicum AB (NASDAQ) - Aussie Stock Forums

Results 1 to 20 of 20
  1. #1

    Post IMMU - Immunicum AB (NASDAQ)

    Immunicum is Swedish Biotech Company listed on NASDAQ OMX First North and develops therapeutic cancer vaccines with INTUVAX being their flagship model. The company has a total of five projects in their pipeline and their main cancer vaccine, INTUVAX, currently recruiting 90 patients for a clinical phase II study for kidney cancer (Renal Cell Carcinoma).

    INTUVAX is a therapeutic vaccine based on the company’s COMBIG platform. The vaccine uses allogenic dendric cells (patent protected) and does not need to be loaded with antigens in vitro; instead the vaccine is injected intratumorally and uses the patient’s own tumor as antigen source. INTUVAX has the potential to work in all cancer indications that has a solid tumor. Clinical trials are ongoing for kidney cancer (Phase II) and for liver cancer (Phase I). INTUVAX is also an “off the shelf” product that most likely will be considerably cheaper to produce than other autologous vaccine, e.g. Dendreon’s Provenge.

    The Phase I/II study in kidney cancer (mRCC), combines INTUVAX with Pfizers Sutent. The study has showed amazing survival in a small amount of patients. A total of 11 patients were recruited to the study, five (n=5) with intermediate prognosis and six (n=6) patients with poor prognosis, subgrouping according to so-called MSKCC criteria. The median overall survival after vaccination for the subgroup with poor prognosis is currently at 25 months and has thus already exceeded the expected median overall survival of 5 months with interferon treatment and 9 months with only Sutent treatment. The median overall survival for the intermediate patients is too early to comment on even if the patients already have lived surpassed expected survival.

    In the Phase I/II study in mRCC several interesting data that confirms the synergistic antitumor effect, between tyrosine kinase inhibitors (Sutent) and INTUVAX, has been observed:
    One patient had four brain metastases and all of them went into complete regression and disappeared completely later on. Another patient with extensive sarcomatoid tumor development also showed a partial regression of all metastases. According to documented literature for kidney cancer neither of these two patients should have responded to treatment with tyrosine kinase inhibitors. It is therefore likely that the effect comes from the synergistic of a drug that can inhibit immunosuppression (Sutent) and another drug that can reinforce the immune defense (INTUVAX).

    Company webpage:

    Survival diagrams for the kidney cancer study can be seen here (although with Swedish text):

  2. #2

    Default Re: IMMU - Immunicum AB (NASDAQ)

    They released an interim report 150521 i will post the link here as soon as they have translate it.

  3. #3

    Default Re: IMMU - Immunicum AB (NASDAQ)

    First patient in:


    Annual report 13/14 (read the immune respon on p.13, worldrecord?)


  4. #4

    Default Re: IMMU - Immunicum AB (NASDAQ)

    I would love some comments about the case from you guys/girls down under

  5. #5

    Default Re: IMMU - Immunicum AB (NASDAQ)

    Immunicum nominated to SwedenBIO award 2015


  6. #6

    Default Re: IMMU - Immunicum AB (NASDAQ)

    Hi again.
    Made this slide about Immunicum in english for you non swedish speaking people.

    To bad they didnt won the swedenbio award.
    Attached Thumbnails Attached Thumbnails Immunicum-ShortBriefPresentation.pdf  

  7. #7

    Default Re: IMMU - Immunicum AB (NASDAQ)

    Immunicum had a video presentation 2015-06-08 and what they said about the way forward was:

    Report final data on HCC I/II
    Update on RCC I/II data
    Start of clinical trial in new indication (i think this gonna be with Intuvax and a PD1 inhibitor from a BP, indication might be in coloncancer)
    CD70 preclinical studies

    RCC II POC data
    Partner discussions
    HCC II decision on next step.

    Im also on twitter: https://twitter.com/maq_uet

  8. #8

    Default Re: IMMU - Immunicum AB (NASDAQ)

    The Key Players in Global Kidney Cancer Drugs Market 2015-2019, According to a New Study on ASDReports


  9. #9

  10. #10

    Default Re: IMMU - Immunicum AB (NASDAQ)

    This is old news but shows how much potential Immunicum has

    March 27, 2015
    Immunicum supplies NCI research with technology for CRISPR/Cas9 system for research on new drugs for cancer and AIDS


    And im very curious if anyone consider or allready bought some shares in Immunicum after reading my thread. Please reply on this thread if you have.

    Follow me on twitter for more news/updates, alot of people on twitter have shown interest in the company.

  11. #11

    Default Re: IMMU - Immunicum AB (NASDAQ)

    I rest my case.... They are all still alive


  12. #12

  13. #13

    Default Re: IMMU - Immunicum AB (NASDAQ)

    Immunicum CSO is going to speak at ICI Europe 16-18 November | Bad Homburg, Germany


  14. #14

    Default Re: IMMU - Immunicum AB (NASDAQ)

    Immunicum updates safety and survival data in phase I/II liver cancer study with INTUVAX: http://www.immunicum.se/wp-content/u...HCC-update.pdf

  15. #15

    Default Re: IMMU - Immunicum AB (NASDAQ)

    Immunicum provides Ad5PTDf35 adenovirus technology to Rutgers Cancer Institute: http://globenewswire.com/news-releas...Institute.html

  16. #16

    Default Re: IMMU - Immunicum AB (NASDAQ)

    Immunicum in collaboration with Karolinska Institute submits an application for starting a clinical study with INTUVAX® in Gastrointestinal Stromal Tumor (GIST).


  17. #17

    Default Re: IMMU - Immunicum AB (NASDAQ)

    Sometimes next year it will be easier for you to buy immunicum shares


    This really shows confidence from the board

  18. #18

    Default Re: IMMU - Immunicum AB (NASDAQ)

    Immunicum’s patent application regarding the cancer immune primer INTUVAX will be granted in Europe


  19. #19

    Default Re: IMMU - Immunicum AB (NASDAQ)

    Cant complain about their results.


  20. #20

    Default Re: IMMU - Immunicum AB (NASDAQ)

    Immunicum reports updated data from the IN- TUVAX phase I/II study in liver cancer and an- nounces plan for the continuation of the study


Similar Threads

  1. Ya gotta love the NASDAQ
    By wayneL in forum International Markets
    Replies: 8
    Last Post: 30th-September-2016, 07:18 PM
  2. Dow Jones/Nasdaq!
    By Joe Blow in forum International Markets
    Replies: 78
    Last Post: 19th-March-2010, 12:43 PM
  3. Nasdaq ..The sell off .....
    By MARKETWAVES in forum International Markets
    Replies: 5
    Last Post: 12th-June-2005, 02:37 AM
  4. Nasdaq......( the rally )
    By MARKETWAVES in forum International Markets
    Replies: 2
    Last Post: 4th-June-2005, 06:06 AM
  5. Nicolas Nasdaq E-mini Trading Journal
    By nicolas in forum International Markets
    Replies: 6
    Last Post: 18th-December-2004, 12:32 PM

Tags for this Thread


Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
Aussie Stock Forums